We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
- Authors
Hersh, Carrie M; Kieseier, Bernd; Moor, Carl de; Miller, Deborah M; Campagnolo, Denise; Williams, James R; Fitzgerald, Kathryn C; Xiong, Kuangnan; McGinley, Marisa P; Hyland, Megan; Rudick, Richard A; Ziemssen, Tjalf; Koulinska, Irene
- Abstract
Background: Optimizing multiple sclerosis treatment warrants understanding of changes in physical, mental, and social health. Objective: To assess the impact of natalizumab on Quality of Life in Neurological Disorders (Neuro-QoL) scores. Methods: Annualized change in T-scores and likelihood of ≥5-point improvement over baseline were calculated for each Neuro-QoL domain after natalizumab initiation. Comparisons with ocrelizumab-treated patients were conducted after propensity score weighting and adjustment for relevant co-medications, year, and drug-year interaction. Results: Among 164 natalizumab patients analyzed, 8 of 12 Neuro-QoL domains improved significantly, with greater improvement in patients with abnormal baseline Neuro-QoL. In the subgroup comparison of natalizumab-treated (n = 145) and ocrelizumab-treated (n = 520) patients, significant improvement occurred in 9 of 12 and 4 of 12 domains, respectively. The difference between groups was statistically significant for positive affect and well-being (p = 0.02), sleep (p = 0.003), and satisfaction with social roles and activities (SRA) (p = 0.03) in the overall population and for emotional and behavioral dyscontrol (p = 0.01), participation in SRA (p = 0.0001), and satisfaction with SRA (p = 0.02) in patients with abnormal baseline Neuro-QoL. Conclusions: Natalizumab can produce clinically meaningful improvements in mental and social health. Such improvements are unlikely to be primarily driven by expectation bias, as their magnitude exceeded improvements with another high-efficacy therapy, ocrelizumab.
- Subjects
NATALIZUMAB; QUALITY of life; MULTIPLE sclerosis; SOCIAL role; NEUROLOGICAL disorders; STUDENT adjustment
- Publication
Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, Vol 7, Issue 2, p1
- ISSN
2055-2173
- Publication type
Article
- DOI
10.1177/20552173211004634